B24 Assessment of immune system activation status during the course of disease in huntington’s disease mouse model by Pido-Lopez, J et al.
ASSESSMENT OF IMMUNE SYSTEM ACTIVATION STATUS DURING THE COURSE OF HUNTINGTON’S 
DISEASE IN HD MOUSE MODELS 
 
Jeffrey Pido-Lopez1,2, Ralph Andre1,3, Sophie A. Franklin1,2, Sarah J. Tabrizi1,3 and Gillian P. Bates1,2 
 
 
1UCL Huntington’s Disease Centre. 2Sobell Dept. Motor Neuroscience, UCL Institute of Neurology, 
University College London, London, UK. 3Dept. Neurodegenerative Disease, Institute of Neurology, 
University College London, London, UK. 
 
 
BACKGROUND 
A number of neurodegenerative diseases, characterised by progressive and selective death of neurons 
in the CNS, are accompanied by activation of the peripheral immune system. In Huntington’s disease 
(HD), clinical and animal studies show elevated immune factors that are hallmarks of immune activity 
and the use of immunosuppressive regimens have shown beneficial effects in HD mice.. These results 
suggest a contributory role of the immune system in HD pathology, with immune based interventions 
offering potential therapeutic strategy to disease.  
 
AIM 
To assess peripheral and central nervous system (CNS) immune system activity in HD mouse models 
during disease course to determine if / when peripheral immunomodulation will be relevant for HD 
treatment. 
 
METHOD 
R6/2 mice were investigated pre and post-symptomatic stages for immune activity in the brain and 
periphery through the assessment of gene expression and protein levels of interleukin (IL)-1, IL-6, IL-
10, IL-17 and tumor necrosis factor (TNF) cytokines. Gene and cell surface (flow cytometry) 
expression of monocyte and macrophage activation (CD40 and OX40l) and T cell activation (OX40 and 
CD25) markers were also measured. 
 
RESULTS 
At 14 weeks old (late-stage disease) cytokines and cell surface markers are elevated in several 
peripheral compartments as well as the brain. At 8 weeks (pre-symptomatic stage) however, immune 
activity is detectable in the periphery but not in the brain. 
 
CONCLUSION 
Immune activity in the periphery precedes immune activation in the CNS suggesting the peripheral 
immune system may promote activation of the CNS immune system during HD, possibly through the 
secretion of pro-inflammatory factors that can to cross the blood brain barrier. Additionally, myeloid 
immune cells in the CNS and periphery display differing activated phenotypes during late stage HD 
with microglial cells presenting a predominantly M1 phenotype while monocyte/macrophages show 
a M2 predominating phenotype.     
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